whatshot

ATHX   $0.1002  2.14% Market Closed

Athersys Inc
show_chart Advanced Chart of ATHX
Last Events:

2023-08-09 Trend pattern changed from нисходящий треугольник to нисходящий клин.

2023-08-06 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-03 Signal in EMA100 changed from n/a to bearish reversal. 2023-02-14 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.

2023-08-03 Trend Power changed from almost flat to .

2023-08-03 Trend changed from turning up to down and flat.

2023-08-02 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-02 Signal in EMA100 changed from bearish reversal to n/a. 2022-07-29 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.

Current temperature: 1.57
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 5.50
Mean unverified/preliminary 5.50 / 5.50
Target Price Low / High 5.50 / 5.50
Median / STD DEV 5.50 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd None Sell None
stoch Sell None None
ma20 Sell Sell Sell
ma50 Sell None None
ma100 Sell Sell None
Candlestick PatternOct. 16, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US04744L2051
ceo Mr. Daniel A. Camardo M.B.A.
Website https://www.athersys.com
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.